Diabetes and Endocrinology Topic Homepage
Diabetes and Endocrinology Overview
The endocrine system, through its organs and glands, produces and secretes hormones which control and regulate several body functions: reproduction and sexual differentiation, development and growth, homeostasis, regulation of metabolism and nutrient supply.1,2
The thyroid, for example, through the secretion of the hormones T4 and T3, regulates the development of different organs, notably the brain (neuronal...
Cancer can develop within the thyroid gland. Although it is a seldom cancer with 1% of all malignancies registered in UK, it constitutes more than 90% of the cancers of the endocrine glands.3 Thyroid cancer is more common in women than in men, with an incidence around 2.5 times more in the UK in 2010 (1900 new cases for women versus 700 for men).4 There are 4 main types of thyroid cancer: papillary thyroid cancer (60% of the thyroid cancers), follicular thyroid cancer (15%), medullary thyroid cancer (5-10%) and anaplastic thyroid cancer (5%).2
The incidence of many endocrine-related diseases has been increasing in humans (breast cancer, prostate cancer, testicular cancer, obesity, diabetes and infertility) for the last 50 years.5,6
With 347 million people worldwide having diabetes, this condition constitutes the main endocrine disease. Of this number 10% are suffering from type 1 and 90% from type 2.7 Type 2 diabetes is even diagnosed in children and adolescents.1
Moreover, although preventable by diet and physical activity, overweight and obesity have increased twice since 1980 and now represent the 5th leading risk for global death.8 According to WHO, overweight is defined by a body mass index (BMI) ≥ 25 kg/m2 and obese by a BMI ≥30 kg/m2.
In 2008, 1.4 billion adults were overweight and 500 million were obese.
In 2011, more than 40 million children under 5 years old were overweight. WHO estimates that “44% of the diabetes burden, 23% of the ischaemic heart disease burden and 7 to 41% of certain cancers burden are attributable to overweight and obesity”.8
Additionally, some endocrine-related effects in wildlife populations have been observed and some chemicals with endocrine disrupting properties linked to disease outcomes have been identified in the laboratory.1,6
Those chemicals are called “Endocrine Disruptors Chemicals” (EDCs). The International Programme on Chemical Safety (IPCS) is a joint programme of WHO, United Nations Environment Programme (UNEP) and the International Labour Organization, giving the following definitions: “An endocrine disruptor is an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse health effects in an intact organism, or its progeny, or (sub) populations” and “A potential endocrine disruptor is an exogenous substance or mixture that possesses properties that might be expressed to lead to endocrine disruption in an intact organism or its progeny, or (sub) populations”.6
The endocrine disruptors can be natural, like the phytoesrogens (e.g. isoflavonoids in soya beans) or synthetic like pesticides (e.g. dichlorodiphenyl trichloroethane (DDT)). Exposure can be by ingestion, inhalation, dermal absorption, transplacental or by breast milk.1
The endocrine disruptors can act: directly on the hormone receptors, alter the synthesis and the metabolism of the hormones or of the hormone receptors or possibly change the cell sensitivity to a specific hormone.1,6
They can act on nuclear receptors, non-nuclear steroid hormone receptors, non-steroid receptors, orphan receptors, enzymatic pathways involved in steroid biosynthesis and/or metabolism and they can have simultaneous actions on different receptors.5,6
The severity of the effects related to the endocrine disruption depends on different factors, notably age. As fetuses and infants are in development, they are more sensitive.1,5,6
The effects of the endocrine disruptors may appear later as there is latency of exposure and some synergistic effects are possible, even when the EDCs are combined at low doses that individually do not produce observable effects.1,6 These molecules are lipophiles and accumulate in adipocytes.1,5,6 They also produce non-linear dose responses and show tissue specific effects.6
The effects of EDCs can be various. Precocious puberty has been associated to exposure to DDT, Polychlorinated Biphenyls (PCBs) and phtalates (used as a plasticizers in polyvinyl chloride (PVC), cosmetics and fragrance).1
The thyroid gland which regulates the brain development can be disrupted, by, for example: PCBs, detergent derivative monylphenol, plasticiser dibutylphtalate, plastic triclosan, polybromintaed phenyls and some UV-filters.1
The main messages given by WHO and UNEP are that the EDCs are everywhere and their numbers are increasing. People are exposed to mixtures occurring at early life stages. All sources of EDCs aren’t known.6
Currently, around 800 chemicals are considered as EDCs or potential EDCs but just a few of them have been studied to assess their impact.6 According to WHO, it is important that the physicians “report cases that can be related to environmental exposure as they may be sentinel cases”.1
1. World Health Organization. Children’s Health and the Environment: Endocrine Disorders and Children. October 2011. Available at: http://www.who.int/ceh/capacity/endocrine.pdf, accessed the 11th of March 2013.
2. Beers M.H. et al. The Merck manual of medical information. Merck research laboratories. Second home edition. 2003 ; 937-975.
3. Vanderpump M.P.J. The epidemiology of thyroid diseases. Br Med Bull (2011) 99 (1): 39-51.
4. Cancer Research UK. Thyroid Cancer key facts. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/thyroid-cancer/ accessed the 11th of March 2013.
5. De Coster S. et al. Endocrine-Disrupting Chemicals: Associated Disorders and Mechanisms of Action. J Environ Public Health. 2012; 2012: 713696.
6. World Health Organization / United Nations Environment Programme. State of the Science of Endocrine Disrupting Chemicals – 2012. Available at: http://www.who.int/iris/bitstream/10665/78101/1/9789241505031_eng.pdf, accessed the 11th of March 2013.
7. World Health Organization. Diabetes - Fact Sheet N° 312, March 2013. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/, accessed the 11th of March 2013.
8. World Health Organization. Obesity and overweight - Fact Sheet N° 311, March 2013. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/index.html, accessed the 11th of March 2013.
Content on this page
Drug News
Fasiglifam (Takeda) success in Phase III trial for treatment of Type 2 Diabetes
20-05-2013
Takeda Pharmaceutical Company Limited announced results of a Phase III clinical trial (CCT-003) of fasiglifam (TAK-875) for the treatment of Type 2 Diabetes presented at the 56th Annual Meeting of the Japan Diabetes Society.
The results show that 25 mg and 50 mg fasiglifam, when administered once-daily, showed statistically significant and clinically relevant HbA1c lowering effect...
Results positive for Afinitor (Novartis) in BOLERO-3 study in HER2 positive Breast Cancer
19-05-2013Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced Breast Cancer showed that Afinitor (everolimus) tablets, from Novartis, in combination with Herceptin (trastuzumab) and vinorelbine significantly extended progression-free survival (PFS) after prior therapy when compared to treatment with placebo plus trastuzumab and vinorelbine, meeting the study's primary...
FDA approves Xofigo (Bayer HealthCare) for Prostate Cancer
17-05-2013The FDA has approved Xofigo (radium Ra 223 dichloride), from Bayer HealthCare, for the treatment of patients with castration-resistant Prostate Cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo (formerly Alpharadin) is the first and only alpha particle-emitting radioactive therapeutic agent approved by the FDA that has demonstrated improvement in overall...
Diabetes and Endocrinology Drug Data - A-Z
Possible searches include drugs or medicines (by brand, generic ingredient or drug class), diseases, conditions and more.
Recent Drug Updates
JANUVIA 25mg, 50mg, 100mg film-coated tablets
03-05-2013For adult patients with type 2 diabetes mellitus, Januvia is indicated to improve glycaemic control: as monotherapy • in patients inadequately controlled by diet and exercise alone and for ...
Victoza 6 mg/ml solution for injection in pre-filled pen
28-03-2013Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control: In combination with: – Metformin or a sulphonylurea, in patients with...
Zemplar Soft Capsules 2 mcg
19-03-2013Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease Stages 3 and 4) patients and chronic renal...
Clinical Guidelines
Global Guideline for Type 2 Diabetes
Oct 2012In 2005 the first IDF Global Guideline for type 2 diabetes was developed. This presented a unique..
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Jun 2012Treatment of hypothyroidism is today predominantly with L-T4: its long half-life of 1 week is..
Online CME
Clinical Review - Type 2 diabetes mellitus
Apr 2013Type-1 Diabetes Mellitus
Apr 2013Clinical Trials
A Multicenter Phase II Pilot Open Label (BKM120)
04-04-2013Due to the high frequency of activation of PI3K and downstream effectors in progressive, recurrent and poorly differentiated cancers, inhibition of the PI3K signaling pathway with BKM120, a potent pan class I PI3K inhibitor, represents a particularly relevant therapeutic target and should be properly evaluated in..
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)
04-04-2013This randomized trial examines the effectiveness of chemoradiotherapy compared to chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of FOLFIRINOX in patients with locally advanced, non resectable and non-metastatic pancreatic cancer. Chemotherapeutic agent in chemoradiotherapy is..
Medical Videos
Medical Journal Abstracts
Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes
Pediatric Diabetes
Jan 2013
Objective: To examine whether insulin requirements and diabetes control differ between adolescents and adults with cystic fibrosis related diabetes (CFRD). Methods: All CFRD patients on insulin therapy seen at the University of Minnesota outpatient clinic from 1 January 2011 to 1 June 2012 were identified. Hemoglobin..
Evaluation of glycated hemoglobin and fetal hemoglobin-adjusted HbA1c measurements in infants
Pediatric Diabetes
Jan 2013
Background: As the presence of fetal hemoglobin (HbF) affects the accuracy of hemoglobin A1c (HbA1c) analysis methods, HbA1c measurement may not be a good indicator for patients with neonatal diabetes mellitus, whereas glycated albumin (GA) may be a good indicator. Objective: To investigate whether total glycated..
Medical Apps
Living medical textbook - Diabetes - Free
Diabetes Reference - £1.23
Diabetes - A Living Medical eTextbook - Free
Endocrinology (Hormones) - £1.85
Social Media
Can hypoglycaemia occur in otherwise normal folk?
on doc2doc... or there is a particular susceptibility and I note the clash of hormones suggested above. It is easy to blame alcohol - but what is the evidence that ...
Can hypoglycaemia occur in otherwise normal folk?
on doc2doc... having high insulin levels, most of the time. When we start to get lowish blood sugars, and turn on our gluconeogenesis, our insulin levels fall ...
Can hypoglycaemia occur in otherwise normal folk?
on doc2doc... of insulin to rise of post prandial glucose. During the third hour after a carbohydrate rich meal they have surges of very high levels of insulin and ...


